# Evolus, Inc.

Type: Company (EOLS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/evolus-inc
Canonical HTML page: https://getbiobrief.com/entity/evolus-inc

## Timeline

- **2026**: Anticipated FDA Approval — Expected regulatory clearance for the first Evolysse filler products.
- **2026**: Commercial Launch — Planned U.S. launch of the Evolysse filler portfolio to aesthetic injectors.
- **2025-Q4**: Q4 Earnings — Company reports record revenue and market share for Jeuveau.
- **2024-Q4**: Filler Partnership — Evolus expands partnership with Symatese for the Evolysse dermal filler line.

## Recent coverage (1 stories)

### Evolus Q4 2025: Jeuveau Market Share Surges as Dermal Filler Launch Approaches
2026-03-05 22:46:48 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Evolus, Inc. reported strong Q4 2025 results, driven by the continued market share expansion of its flagship neurotoxin, Jeuveau, and progress in its international rollout. The company remains on track to transform into a multi-product aesthetics platform with the anticipated 2026 launch of its Evolysse dermal filler line.
Full story: https://getbiobrief.com/story/evolus-q4-2025-earnings-analysis-jeuveau-evolysse

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.